Bedford, United States
Genabio Diagnostics is a leading global producer of over-the-counter self-testing products, boasting a remarkable sales record of over $100 million in the last three years. The company's wide customer base extends across the USA, Canada, the UK, Japan, and India. A notable feature of their product range is the FDA approval, including the sought-after COVID-19 self-test. These products are available in numerous locations, including esteemed pharmacy chains like Walgreens, prominent hospitals such as NYU Langone Health, accredited laboratories like SV Diagnostics Labs and Molecular Testing Labs, and various government departments.
In 2023, Genabio achieved a significant milestone by commencing their listing and financing efforts in Hong Kong. Concurrently, they are dedicated to strengthening their brand identity and emphasizing clinical research within the United States. This focus on research and development aligns with their expansion plans, involving an increase in production capacity in both the United States and China.
The overarching vision of Genabio is to become the foremost provider of self-testing solutions globally, offering precise, user-friendly, and cost-effective health diagnostics for individuals worldwide. Their mission is to enhance global health awareness and accessibility by delivering quality, FDA-approved self-test kits, driving innovation, and expanding their reach to ensure individuals can monitor their health with precision and convenience. Genabio was founded in 2019 and operates within the manufacturing industry from their headquarters in the United States.
